Melvin Md Sharoky Sells 10,000 Shares of Insmed (NASDAQ:INSM) Stock

Key Points

• Melvin Md Sharoky, a director at Insmed, sold 10,000 shares of the company's stock for approximately $1.45 million, resulting in a 3.67% decrease in his position.
• Insmed's stock fell by 1.9% on Monday, trading at $143.14, while the company reported a negative earnings per share of ($1.70) in its last quarterly earnings, missing analyst expectations.
• Equities research analysts have upgraded Insmed’s stock, with target prices ranging from $115.00 to $165.00, as the company is forecasted to have a consensus rating of "Moderate Buy".

Insmed, Inc. (NASDAQ:INSM - Get Free Report) Director Melvin Md Sharoky sold 10,000 shares of the business's stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the transaction, the director owned 262,675 shares in the company, valued at $38,190,318.25. This trade represents a 3.67% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Melvin Md Sharoky also recently made the following trade(s):

• On Wednesday, August 20th, Melvin Md Sharoky sold 10,000 shares of Insmed stock. The stock was sold at an average price of $129.50, for a total value of $1,295,000.00.

Insmed Stock Down 0.8%

Shares of NASDAQ INSM traded down $1.10 during mid-day trading on Friday, hitting $144.76. The company had a trading volume of 5,624,066 shares, compared to its average volume of 1,971,056. Insmed, Inc. has a one year low of $60.40 and a one year high of $149.08. The company has a market capitalization of $30.60 billion, a PE ratio of -25.35 and a beta of 0.97. The firm has a 50-day simple moving average of $124.17 and a two-hundred day simple moving average of $94.19. The company has a current ratio of 6.68, a quick ratio of 6.33 and a debt-to-equity ratio of 0.45.

Insmed (NASDAQ:INSM - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.The business had revenue of $107.42 million during the quarter, compared to the consensus estimate of $104.06 million. During the same period in the prior year, the firm earned ($1.94) EPS. The business's revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. On average, equities analysts expect that Insmed, Inc. will post -4.56 EPS for the current year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the stock. Truist Financial boosted their target price on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. The Goldman Sachs Group lifted their price target on shares of Insmed from $114.00 to $142.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. Stifel Nicolaus upped their target price on shares of Insmed from $121.00 to $145.00 and gave the company a "buy" rating in a report on Thursday, August 14th. Royal Bank Of Canada raised their price target on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a research report on Friday, August 8th. Finally, UBS Group lifted their price target on Insmed from $124.00 to $133.00 and gave the stock a "buy" rating in a research note on Friday, August 8th. Sixteen equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $139.86.

Hedge Funds Weigh In On Insmed

Several institutional investors and hedge funds have recently bought and sold shares of INSM. M&T Bank Corp increased its stake in Insmed by 4.7% in the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after buying an additional 147 shares in the last quarter. Snowden Capital Advisors LLC boosted its stake in shares of Insmed by 2.5% during the 4th quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock worth $456,000 after acquiring an additional 158 shares in the last quarter. First Horizon Advisors Inc. raised its holdings in Insmed by 24.8% in the 2nd quarter. First Horizon Advisors Inc. now owns 936 shares of the biopharmaceutical company's stock valued at $94,000 after acquiring an additional 186 shares during the last quarter. ORG Partners LLC boosted its position in shares of Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 196 shares during the period. Finally, Cullen Frost Bankers Inc. raised its holdings in shares of Insmed by 164.9% in the 1st quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.